Nelson Advisors: The New World of Earn-Outs in European HealthTech, MedTech and Health AI

Nov 17, 2026By Nelson Advisors

NA

The earn-out used to be the clause everyone hoped to delete before signing. In European HealthTech, MedTech and Health AI it has quietly become the deal itself. A founder selling a Series B diagnostics company in Munich, a PE-backed buyer consolidating radiology AI across the Nordics, a US strategic picking up a UK remote-monitoring business: in each case, a meaningful slice of the price, often 20 to 50 per cent, now sits behind a set of post-completion conditions.
  
Three forces pushed it there. First, the valuation gap. Health companies raised at 2021 multiples and are selling into a market that prices them on 2026 revenue and 2026 evidence. Neither side can agree on a number, so they agree on a formula instead. Second, regulatory timing. A company whose value depends on a CE mark under the EU Medical Device Regulation, an AI Act conformity assessment, a NICE recommendation or a German DiGA listing is worth very different amounts depending on whether those arrive. 
  
The buyer will not pay today for a decision a notified body makes in eighteen months. Third, the shape of the assets themselves. Much of what is being bought in Health AI is a model, a dataset, a handful of clinical champions and a pipeline of hospital pilots. None of that is bankable without the people who built it staying long enough to convert it.
  
So the earn-out has stopped being a tail on the deal and has become its spine. It is where the money is, where the people are tied in, and where most of the post-signing arguments happen. 
  
Our article below walks through how the modern European health earn-out is actually built: the holding structures, the equity roll, the multi-KPI scorecards, the clawbacks, the people terms, and the risks each side is carrying when they sign.

Source: https://www.healthcare.digital/single-post/nelson-advisors-the-new-world-of-earn-outs-in-european-healthtech-medtech-and-health-ai